Mesoblast’s Revascor Gains FDA Designation Boost
Mesoblast (MESO) has released an update.Pick the best stocks and maximize your portfolio:Discover top-rated stocks from highly ranked analysts ...
Mesoblast’s Revascor improves survival in heart failure patients
Mesoblast Limited announced a key publication in the November 2024 online issue of the prestigious peer-reviewed European Journal of Heart Failure, which re ...
Mesoblast’s Revascor Therapy Shows Promise in Heart Failure
Mesoblast (MESO) has released an update. Mesoblast’s allogeneic cell therapy, Revascor, has shown promising results in ...
Nasdaq7d
Mesoblast: FDA grants RMAT designation to Revascor
Mesoblast (MESO) announced the United States FDA has granted its second generation allogeneic, STRO3-immunoselected, and industrially manufactured stromal cell therapy, Revascor, Regenerative ...
Morningstar10d
Revascor Improves Survival and Reduces Major Morbidity in High-Risk Ischemic Heart Failure Patients With Inflammation
This identifies the target HFrEF population that is responsive to REVASCOR therapy. DREAM-HF’s lead investigator, Dr. Emerson C. Perin, MD, PhD, FACC, Medical Director at The Texas Heart ...
Pharmabiz6d
Mesoblast’s Revascor gets US FDA’s regenerative medicine advanced therapy designation in children with congenital heart disease
Mesoblast’s Revascor gets US FDA’s regenerative medicine advanced therapy designation in children with congenital heart disease: New York Friday, December 6, 2024, 18:00 Hrs [ ...
Finance News Network7d
Mesoblast's Revascor gets FDA nod, but shares dip
reducing inflammation and preventing the immune system from attacking healthy tissues, creating a favourable environment for tissue growth ("immunomodulation").
WREG7d
FDA Grants Revascor® (Rexlemestrocel-L) Regenerative Medicine Advanced Therapy (RMAT) Designation in Children with Congenital Heart Disease
Mesoblast Chief Executive Silviu Itescu said: “We appreciate FDA’s support in designating REVASCOR both RMAT and RPD status, a recognition of the potential impact of our therapy on the long ...
Yahoo Finance9d
Revascor Improves Survival and Reduces Major Morbidity in High-Risk Ischemic Heart Failure Patients With Inflammation
This identifies the target HFrEF population that is responsive to REVASCOR therapy. DREAM-HF’s lead investigator, Dr. Emerson C. Perin, MD, PhD, FACC, Medical Director at The Texas Heart Institute, ...